Top Story

Maintenance pazopanib extended PFS, not OS in ovarian cancer

October 24, 2014

Maintenance therapy with pazopanib extended PFS by about 45% among women with ovarian cancer whose disease did not progress during first-line chemotherapy, according to results of a phase 3 study.

However, the maintenance regimen did not appear to confer an OS benefit.

In the Journals

Brief intervention improved sexual function after oophorectomy

October 24, 2014
Women with the BRCA1 or BRCA2 mutations who underwent risk-reducing salpingo oophorectomy and experienced menopause-related sexual dysfunction and associated…
FDA approvals

FDA approves Obizur for acquired hemophilia A

October 24, 2014
The FDA approved Obizur for the treatment of bleeding disorders in adults with acquired hemophilia A.The development of acquired hemophilia A — a non-genetic…
In the Journals

Efficacy of VTE chemoprophylaxis in otolaryngology patients varied by subgroup

October 24, 2014
The efficacy and safety of venous thromboembolism chemoprophylaxis for individuals undergoing otolaryngologic surgery varied based on Caprini risk score and the type of…
More News Headlines »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
figure

Nomogram predicted recurrence risk among women who underwent APBI

September 26, 2014
Jessica Wobb, MD, senior resident in radiation oncology at Beaumont Health System in Birmingham, Mich., describes how…
More »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »